Published in final edited form as:

Prostate. 2014 December ; 74(16): 1579–1588. doi:10.1002/pros.22871.

8q24 Risk Alleles and Prostate Cancer in African-Barbadian Men

Cheryl D. Cropp^{1,6}, Christiane M. Robbins^{2,6}, Xin Sheng³, Anselm J.M. Hennis⁴, John D. Carpten², Lyndon Waterman⁴, Ronald Worrell⁴, Tae-Hwi Schwantes-An¹, Jeffrey M. Trent², Christopher A. Haiman³, M. Cristina Leske⁵, Suh-Yuh Wu⁵, Joan E. Bailey-Wilson¹, and Barbara Nemesure⁵

¹Computational and Statistical Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore, Maryland ²Integrated Cancer Genomics Division, Translational Genomics Research Institute (TGen), 445 N. Fifth Street, Phoenix, Arizona

³Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California ⁴Chronic Disease Research Centre and Faculty of Medical Sciences, The University of the West Indies, Bridgetown, Barbados ⁵Department of Preventive Medicine, Stony Brook University Medical Center, Stony Brook, New York

Abstract

BACKGROUND—African American men (AA) exhibit a disproportionate share of prostate cancer (PRCA) incidence, morbidity and mortality. Several genetic association studies have implicated select 8q24 loci in PRCA risk in AA. The objective of this investigation is to evaluate the association between previously reported 8q24 risk alleles and PRCA in African-Barbadian (AB) men known to have high rates of PRCA.

METHODS—Ten previously reported candidate tag SNPs were genotyped and/or imputed in the 8q24 region in 532 AB men with PRCA and 513 AB controls from the Prostate Cancer in a Black Population (PCBP) study.

RESULTS—Rs2124036 was significant in AB men, (OR = 2.7, 95% CI (1.3–5.3), P=0.005, Empirical (max(T), corrected for multiple testing) P = 0.03) for the homozygous C/C genotype. Only a single SNP from this region remained statistically significant in our analysis of our AB population. These results may indicate the presence of a founder effect or due to the chosen SNPs not tagging an ancestral haplotype bearing the 8q24 risk allele(s) in this population or could reflect inadequate power to detect an association. We conducted a meta-analysis including our AB population along with two additional African Caribbean populations from Tobago and Jamaica for SNPs rs16901979 and rs1447295. Meta-analysis results were most significant for rs16901979 A allele (Z score 2.73; p=0.006) with a summary OR= 1.31 (95% CI: 1.09–1.58).

CONCLUSIONS—Additional studies are needed to provide deeper genotype coverage to further interrogate the 8q24 region to understand its contribution to PRCA in this population.

Correspondence should be addressed to: Joan E. Bailey-Wilson, National Human Genome Research Institute, National Institutes of Health, 333Cassell Drive, Suite 1200, Baltimore, MD 21224. jebw@mail.nih.gov, office phone: 443-740-2921, FAX: 443-740-2165, administrator: 443-740-2922.

⁶These authors contributed equally to this work

Introduction

African American men (AA) maintain a disproportionate burden of prostate cancer (PRCA) incidence, treatment failures and mortality (1–3). Recently several genetic association studies have implicated loci surrounding 8q24 as a potential region of PRCA risk in AA (4–14) while other studies have not corroborated these findings after correcting for local admixture within the 8q24 region(6). To elucidate the genetic determinants for cancer patterns in AA and address the noted inconsistencies, it is useful to study populations across the African Diaspora (15). African-Barbadians (AB) share a common West African heredity with AA but have lower rates of admixture, thus potentially enhancing the discovery of ancestrally-related genetic factors (16–18). AB men among other African Caribbean populations are known to have high rates of PRCA incidence and mortality. A recent study found that although PRCA risks are lower for AB compared to AA, the mortality rates were higher for AB than for their AA counterparts (mortality rates in AB ranged from 63.2 to 101.6 per 100,000 compared to 51.1 to 78.8 per 100,000 among AA) (19,20) thus representing a unique group that may assist in disentangling some of the key genetic determinants of PRCA common in populations of African origin.

In this candidate region investigation, we studied 10 previously reported SNPs in the 8q24 region in 532 AB men diagnosed with PRCA and 513 AB controls (N=1,045) who participated in the Prostate Cancer in a Black Population (PCBP) study. The purpose of this investigation was to determine whether any of the previously reported risk alleles were associated with PRCA in this Afro-Caribbean population. All study participants provided informed consent and all protocols conformed to the Declaration of Helsinki.

Materials and Methods

The PCBP is a population-based case-control study conducted between July 2002 and January 2011, which included 1,007 newly-diagnosed and histologically confirmed men with PRCA and 1,005 male controls free of PRCA at the time of their study visit. Controls were randomly selected from a national database and frequency age-matched to the cases by 5-year age groups. Among the study participants, 963 cases and 941 controls self-reported their race as AB and a subset of consecutive samples collected through January 2009 (532 cases and 513 controls; n=1,045) were genotyped for the present investigation(21).

Standardized protocols were used in the collection of demographic and lifestyle data, anthropometric measurements, medical and family history information and blood samples (to measure PSA, HbA1c and to test for genetic variants) (21).

Genotypes

Genomic DNA was isolated from buffy coats using the PUREGENE DNA Isolation system from Gentra (Qiagen®). DNA was resuspended in TE buffer and quantified by spectrophotometry. Genomic DNA quality control was assessed by UV spectrophotometry, restriction digest and PCR analysis of individual genomic DNA samples. Samples failing two rounds of quality control were re-precipitated to remove potential impurities left over from initial DNA isolation followed by reassessment of quality control. A sample of the

DNA was used for whole genome amplification in order to increase the amount of DNA available. Ten known genetic variants on chromosome 8q24 were genotyped on 858 samples using the SequenomMassARRAY™ genotyping platform with iPLEX™ chemistry according to manufacturer's recommendations. Briefly, iPLEX™ assays were designed utilizing the Sequenom Assay Design software, allowing for single base extension (SBE) designs used for multiplexing. PCR and SBE primer sequences are available upon request. Multiplex assays were performed to amplify 5–10 ng of genomic DNA by polymerase chain reaction (PCR). PCR reactions were treated with shrimp alkaline phosphatase (SAP) to neutralize unincorporated dNTPs. Subsequently, a post-PCR single base extension reaction was performed for each multiplex reaction using concentrations of 0.625 μM for low mass primers and 1.25 μM for high mass primers. Reactions were diluted with 16 μl of H₂O and fragments were purified with resin, spotted onto SequenomSpectroCHIP™ microarrays and scanned by MALDI-TOF mass spectrometry. Individual SNP genotype calls were generated using Sequenom™ TYPER 4.0 software, which automatically calls allele specific peaks according to their expected masses. Duplicate controls were used for each DNA plate as well as each SequenomSpectroCHIP™ microarrays.

A portion of our AB cohort (N=458; 234 cases and 224 controls) was selected for additional genotyping (GWAS and imputed GWAS) as part of a replication phase of a separate collaborative PRCA study (7). The complete methods for this additional genotyping and imputation are described elsewhere (7). These genome-wide results were underpowered and thus did not reveal any significant genome-wide results (see supplemental Figure) but were useful to increase the power of our 8q24 candidate loci study since 187 samples (64 cases and 123 controls) with GWAS and imputed genotypes were not previously included in the candidate region study.

Briefly, the GWAS sample was genotyped using Illumina Infinium Human1M-Duo on 458 samples, 271 of which were also previously genotyped for the 10 candidate SNPs (see above). Eight of our 10 candidate SNPs were genotyped using the Infinium chipset and genotypes for the other two SNPs were imputed in these individuals. We confirmed that the 271 individuals who had genotypes for 8 candidate loci from both platforms gave concordant genotypic results. For the imputation of the two candidate SNPs not on the Infinium chip, post quality control Illumina Infinium genotypes, phased with haplotype data from the founders of the CEU and YRI HapMap phase 2 samples (22) were used to infer linkage disequilibrium patterns. Genome-wide imputation was performed using IMPUTE2(23) with a threshold of $R_{sq} < 0.3$ to filter out poor quality SNPs from the analysis.

All in all, a total of 1,045 individuals (858 with 10 genotyped SNPs from SequenomSpectroCHIP™ and an additional 187 with 8 genotyped SNPs from Infinium Human 1M-Duo assay and 2 imputed SNPs (rs16901979 and rs7818556) were available for analyses.

Statistical Analyses

Power calculations were performed using the QUANTO program (24,25) and the CaTs program (26). With a total sample size of 1,045 (AB cases + AB controls), we estimated the

minimum detectable genotype relative risk (GRR) for carriers of one or two copies of a susceptibility allele (with 90% power at significance levels of $p=0.05$, 0.01 and 0.00001) given different allele frequencies and different population prevalence of disease (27). Based on SEER data from AA across age groups, prevalence of PRCA ranges between 5 and 10%(1). Using these values, the power calculations suggest that this study has adequate power to detect associations of alleles with GRR in the range of 1.28 to 1.63 for $p=0.05$ (1.3–1.8 for $p=0.01$, as long as the allele frequency is between 5 and 50% and the mode of inheritance is either log-additive or dominant). Even for rare dominant or log-additive risk alleles with only 1% frequency, we have enough power to detect them if the GRR is at least 2.5. For a recessive risk allele, power will only be adequate for common risk alleles.

The PLINK (28) program was used to perform quality control of the genotype data, identifying and dropping any samples with low genotype call rates (>0.2 missing genotypes), SNPs with very low genotyping rates (<0.1), and any SNPs that failed tests for Hardy-Weinberg equilibrium ($p=0.001$). A set of 53 ancestry-informative SNPs distributed across the genome were analyzed with the STRUCTURE (17) and EIGENSTRAT (29) programs to detect population stratification and to confirm race given by self-report. Of the total 1,045 subjects genotyped, 532 cases and 513 controls were confirmed to be AB. Four covariates previously associated with risk of PRCA (21,30): age, waist-hip ratio (WHR), PSA, and family history were added to the analysis in order to adjust for any effects on PRCA risk. The dataset was also subdivided and analyzed based on family-history of PRCA as an ordinal variable.

Haploview (31) was used to calculate estimates of linkage disequilibrium (LD) between the marker loci, and to test for association of genotypes and haplotypes to disease status. Upon completion of haplotype structure analysis, genotypic association tests were performed for all individual SNPs and for haplotypes using PLINK (28). All association testing results were corrected for multiple testing using max(T) permutation testing in PLINK (28) which is the family-wise error rate and corrected for multiple testing. This permutation procedure preserves the correlational structure between the SNPs, thus providing a more accurate correction compared to a Bonferroni correction assuming all these tests are independent. The included Figure shows the intermarker LD (measured as R^2) between the SNPs tested here.

A subsequent meta-analysis of the 8q24 region was performed using African Caribbean (AC) populations from Barbados, Jamaica and Tobago(32,33). The allelic odds ratio (OR) and confidence intervals were calculated using the Mantel-Haenszel method using the “rmeta” package in R (34); the fixed effects (Mantel-Haenszel ; “meta.MH”) and random (DerSimonian-Laird ; “meta.DSL”) effects options were selected. In both conditions, Woolf’s test was used to test for heterogeneity. Another program called METAL(35) was also utilized as an alternative meta-analysis method for comparison.

Results

The association analyses included 1,019 AB men (511 PRCA cases and 508 controls) after quality control steps. Principal components analysis of AB samples showed no evidence of population stratification thus there was no need for adjustment. All 10 candidate SNPs

included in the interrogation of the 8q24 region passed our quality control testing and were included in the analysis. This list of candidate SNPs (spanning regions 1–4 on 8q24) and the distribution of minor allele frequencies among cases and controls are presented in Table I. After correcting for multiple tests, no candidate SNPs showed statistically significant differences in allele frequency between cases and controls.

In the genotypic association tests, rs2124036 was found to be statistically significant ($P = 0.005$, OR = 2.7, 95% CI (1.3–5.3), max(T) adjusted $P = 0.03$) when comparing the homozygous C/C genotype to the reference (G/G homozygous) group, while none of the other tested SNP genotypes revealed any significant associations with PRCA after correction for multiple testing. Table II summarizes association test results for the 10 SNPs. Of note, the unadjusted OR for the heterozygous genotype A/C of rs16901979 was nominally significant (OR = 1.4, 95% CI (1.1–1.9), $P = 0.02$). However this finding did not remain significant after multiple testing correction (max(T) adjusted $P = 0.51$). Although previously published associations were not replicated in our AB samples, it is important to note that these 10 SNPs in ABs demonstrate similar direction and magnitude of effect as in previous reports (6,8,11,36–45). We also conducted a meta-analysis of all three AC populations (AB, Tobago and Jamaica) for the two SNPs that were tested in all three samples, rs16901979 and rs1447295 (hereafter called the “in common SNPs”), since it is possible that our non-significant association results were due to inadequate power. Results from a fixed-effects meta-analysis model using METAL (35) were only significant for rs16901979 A allele (Z score 2.7; $p = 0.005$). METAL results for rs1447295 A allele resulted in a Z score of 1.4; $p = 0.16$. Additionally, a random effects (DerSimonian-Laird) meta-analysis in R (Table IVA) revealed a summary OR = 1.21 (95% CI: 1.01–1.46) for rs16901979; Woolf’s test for heterogeneity: $X^2(2) = 0.87$ ($p = 0.65$); estimated random effects variance: 0 for rs16901979. Random effects analysis for rs1447295 demonstrated a summary OR = 1.02 (95% CI: 0.79–1.32); Woolf’s test for heterogeneity: $X^2(2) = 3.18$ ($p = 0.20$); estimated random effects variance: 0.02. These results suggested that lack of power may explain the failure to detect significant PRCA 8q24 associations at these SNPs in the individual AC samples (Table IVA and IVB).

Table III shows the allele frequencies and ORs for a set of four 8q24 SNPs genotyped in our AB sample and the 2 other aforementioned AC samples (in Tobago and Jamaica). The results indicate that the G risk allele frequency for rs7008482 is similar in Barbados and Jamaica (0.9 and 0.88, respectively) as is the A risk allele for rs16901979 (0.51 and 0.5, respectively). Additionally, the frequencies of these alleles were also similar in cases and controls in both Barbados and Jamaica. The A risk allele frequency for rs1447295 among cases in Barbados (0.35) appeared to be between the frequency reported in Tobago (0.33) and Jamaica (0.39) and a similar frequency pattern was noted among controls residing in the 3 Caribbean islands.

Additional analyses, stratifying by the presence or absence of family history, did not change the results (data not shown). Furthermore, haplotype analyses did not reveal any significantly associated haplotypes after correction for multiple testing and adjustment for the given covariates (age, WHR, PSA, and family history) did not improve the significance of the overall results.

Discussion

This work represents the largest cohort of African Caribbean males for the validation of PRCA associated variants in the 8q24 region. Although 8q24 is one of the most validated regions on the genome for harboring genetic variants found to be associated with PRCA risk in populations of African origin (5,6,9,11,12,32,33,36,39,40,44–51), confirmation of these signals in this population are limited. The present investigation evaluated 10 previously interrogated SNPs within the 8q24 region and did not find a strong association between PRCA and any of the selected markers among AB men who participated in the PCBP study.

PRCA susceptibility loci have been identified on 8q24 in various groups (8,10,13,36,39,45), including AA (8,11,36,37,39,40,44) and other populations of African origin (32,33). However, PRCA genetic association studies of chromosome 8q24 in African-Caribbean populations have been somewhat inconsistent. A recent study in Tobago (33) genotyped three candidate SNPs (rs1447295, rs16901979 and rs6983267) within the 8q24 region in 354 PRCA cases and 438 controls. The findings indicated that SNP rs16901979 was found to be associated with a significantly increased risk of PRCA (OR = 1.41, 95% CI (1.02 to 1.95); $p = 0.04$) with risk further increasing for men with early onset PRCA (OR = 2.37, 95% CI (1.40 to 3.99); $p = 0.001$) (33). The two other SNPs evaluated in that study (rs1447295 and rs6983267) were not found to be associated with PRCA risk in that AC population. It should be noted that the results from the Tobago study were not corrected for multiple testing.

A second study, including men from the Caribbean (Jamaica), as well as West Africa (Nigeria and Cameroon), also evaluated the association between PRCA risk and 10 selected SNPs in the 8q24 region (32). Although rs6983561, rs7008482 and rs16901979 were significantly associated with PRCA risk among men from Nigeria and Cameroon, none of the markers was associated with PRCA risk in the Jamaican samples. These findings are consistent with our investigation in which only one of the markers evaluated was found to be associated with PRCA in AB men after correcting for multiple testing.

Interestingly, the MAFs for two previously reported SNPs, rs16901979 and rs1447295, tended to be higher in the AC controls compared to both AA and European-American (EA) men (33,52). The average (range) of MAFs among AA and EA controls for the A risk allele frequency of rs16901979 are 0.43 (range 0.41 to 0.46) and 0.03 (range 0.02 to 0.03) respectively (38–40) compared to 0.47 in the AB control population (0.5 in the Jamaican control population and 0.46 in the Tobagonian control population for rs16901979). The range of the A risk allele of rs16901979 in AC controls is 0.46 to 0.7. Similarly, the average (range) of MAFs for the A allele of rs1447295 are 0.31 (range 0.31 to 0.32) and 0.09 (range of 0.08 to 0.1) for AA and EA controls respectively (6,36,38–40), while the frequency is 0.34 among AB controls from the PCBP. The MAFs for the A risk allele of rs1447295 are 0.31 and 0.37 respectively for Jamaican and Tobagonian AC controls (range 0.31 to 0.55). The noted differences in MAFs between EAs and men of African origin may assist in explaining the significant health disparity in the morbidity and mortality of PRCA that exists in populations of African descent. Furthermore, the somewhat higher allele frequencies found in AA controls compared to AB controls in several other 8q24 risk alleles (*i.e.* rs12547950, rs7008482, rs780321, rs4427136, rs2302793 and rs11780763)(40) may further

explain why none of the previously implicated markers on 8q24 were found to be significantly associated with PRCA in some AC populations.

Another possible explanation for the inconsistent findings in different populations may be the presence of a founder effect in which fewer PRCA risk alleles are in strong linkage disequilibrium with the selected 8q24 variants in AC compared to other populations of African descent. Furthermore, additional markers, yet undiscovered, may be more highly associated with PRCA risk in AC men than other groups. As such, further interrogation of 8q24 and other regions throughout the genome are necessary to elucidate those loci that may influence the risk of PRCA development in AC and other populations of African origin.

Conclusions

Prostate cancer disproportionately affects AA and it is believed that genetic determinants in general, and loci in the 8q24 region in particular, may play a role in explaining some of the disparities that exist in Westernized African populations compared to other groups. Surprisingly, findings from the PCBP, a large, nationwide case-control study of previous PRCA-associated tag SNPs in 8q24 conducted in Barbados, West Indies, found one significant association signal (genotypic test for rs2124036) among 10 SNPs previously reported to be associated with PRCA in other populations of African origin. Although a lack of adequate power remains a plausible explanation for a non-robust 8q24 replication, our results highlight the possibility of genetic differences in PRCA determinants not only between African-derived and non-African descendants but also within populations with shared Western African ancestry. The results from our meta-analysis of three AC populations (Barbados, Tobago and Jamaica) for 2 SNPs genotyped in all 3 samples (greatest significance for rs16901979 A allele) added power to our analyses and led to detection of significant PRCA association with rs16901979, another SNP within the chromosome 8q24 region. Additional studies with larger samples of AC men are needed to further investigate this region (through deeper sequencing) and to discover other PRCA-associated alleles that may be unique to this African-derived population. The exploration of genetic determinants of PRCA will aid in understanding the etiology of this disease and will assist in narrowing the divide between the morbidity and mortality that currently exists between men of African descent and other groups.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We would like to acknowledge the Barbados National Cancer Study Group:

Investigators

Coordinating Center: M. Cristina Leske, MD, MPH; Barbara Nemesure, PhD; Suh-Yuh Wu, MA; Department of Preventive Medicine, Stony Brook Medicine, Stony Brook, NY

Clinical Center: Anselm Hennis, MBBS, PhD, FRCP; Winston Scott Polyclinic, Bridgetown, Barbados

Local Laboratory Center: Lyndon Waterman, PhD; University of the West Indies, Bridgetown, Barbados

Gene Discovery Center: John Carpten, PhD; Jeffrey Trent, PhD; Translational Genomics Research Institute, Phoenix, AZ

NHGRI: Joan E. Bailey-Wilson, PhD; National Human Genome Research Institute, Bethesda, MD

Nutritional Collaborator: Sangita Sharma, PhD; Department of Medicine, University of Alberta, Edmonton, Canada

Barbados Advisory Committee

Professor Trevor A. Hassell, GCM, MBBS, FRCP, FACC; Professor Henry Fraser, GCM, MBBS, FRCP, FACP; Dr. Jerry Emtage, MBBS, FRCS(C); Mr. Selwyn Ferdinand, MBBS, FRCS (Ed); The Honourable Mr. Justice W. Leroy Inniss, QC; Dr. Timothy Roach, MBBS, FRCP; Dr. Gina Watson [PAHO], Dr. Joy St. John [CMO].

Consultant Urologists

Dr. Jerry Emtage, MBBS, FRCS(C); Dr. Dave Padmore, MBBS, FRCS(C); Dr. Irving Smith, MBBS, FRCS.

Departments of Urology, Surgery, Pathology and Radiotherapy, Queen Elizabeth Hospital, Bridgetown, Barbados

Grant Support

CDC is the recipient of an NHGRI Health Disparities Research Fellowship. This project was supported by the Intramural Research Program of the National Human Genome Research Institute, NIH (JEBW, CDC, TSA and contract N01HG25487) and by the National Cancer Institute, NIH (grant R01CA114379).

References

1. National Cancer Institute. SEER Incidence and US Mortality Statistics. 2012. <http://seer.cancer.gov/statistics/>
2. Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis. *International journal of cancer Journal international du cancer*. 2008; 123(2):430–435. [PubMed: 18452170]
3. Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. *Infect Agent Cancerr*. 2009; 4(Suppl 1):S2.
4. Bock CH, Schwartz AG, Ruterbusch JJ, Levin AM, Neslund-Dudas C, Land SJ, Wenzlaff AS, Reich D, McKeigue P, Chen W, Heath EI, Powell IJ, Kittles RA, Rybicki BA. Results from a prostate cancer admixture mapping study in African-American men. *Human genetics*. 2009; 126(5): 637–642. [PubMed: 19568772]
5. Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, Benford ML, Kidd LR, Cooney K, Strom S, Ingles SA, Stern MC, Corral R, Joshi AD, Xu J, Giri VN, Rybicki B, Neslund-Dudas C, Kibel AS, Thompson IM, Leach RJ, Ostrander EA, Stanford JL, Witte J, Casey G, Eeles R, Hsing AW, Chanock S, Hu JJ, John EM, Park J, Stefflova K, Zeigler-Johnson C, Rebbeck TR. Validation of genome-wide prostate cancer associations in men of African descent. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2011; 20(1):23–32.
6. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, Oakley-Girvan I, Whittemore AS, Cooney KA, Ingles SA, Altshuler D, Henderson BE, Reich D. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. *Proc Natl Acad Sci U S A*. 2006; 103(38):14068–14073. [PubMed: 16945910]
7. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, Diver WR, Witte JS, Hsing AW, Nemesure B, Rebbeck TR, Cooney KA, Xu J, Kibel AS, Hu JJ, John EM, Gueye SM, Watya S, Signorello LB, Hayes RB, Wang Z, Yeboah E, Tettey Y, Cai Q, Kolb S, Ostrander EA, Zeigler-Johnson C, Yamamura Y, Neslund-Dudas C,

- Haslag-Minoff J, Wu W, Thomas V, Allen GO, Murphy A, Chang BL, Zheng SL, Leske MC, Wu SY, Ray AM, Hennis AJ, Thun MJ, Carpten J, Casey G, Carter EN, Duarte ER, Xia LY, Sheng X, Wan P, Pooler LC, Cheng I, Monroe KR, Schumacher F, Le Marchand L, Kolonel LN, Chanock SJ, Van Den Berg D, Stram DO, Henderson BE. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. *Nat Genet.* 2011; 43(6):570–573. [PubMed: 21602798]
8. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolonel LN, Frasco M, Wong D, Pooler LC, Ardlie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Altshuler D, Henderson BE, Reich D. Multiple regions within 8q24 independently affect risk for prostate cancer. *Nat Genet.* 2007; 39(5):638–644. [PubMed: 17401364]
 9. Hooker S, Hernandez W, Chen H, Robbins C, Torres JB, Ahaghotu C, Carpten J, Kittles RA. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. *Prostate.* 2010; 70(3):270–275. [PubMed: 19902474]
 10. Robbins AS, Yin D, Parikh-Patel A. Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995–2004. *Am J Epidemiol.* 2007; 166(1): 71–78. [PubMed: 17426038]
 11. Salinas CA, Kwon E, Carlson CS, Koopmeiners JS, Feng Z, Karyadi DM, Ostrander EA, Stanford JL. Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2008; 17(5):1203–1213. [PubMed: 18483343]
 12. Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, Gao C, Ali A, Ravindranath L, Dobi A, Sesterhenn IA, McLeod DG, Srivastava S, Freedman M, Petrovics G. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.* 2010; 19(1):1–8.
 13. Witte JS. Multiple prostate cancer risk variants on 8q24. *Nature genetics.* 2007; 39(5):579–580. [PubMed: 17460686]
 14. Zheng SL, Sun J, Cheng Y, Li G, Hsu FC, Zhu Y, Chang BL, Liu W, Kim JW, Turner AR, Gielzak M, Yan G, Isaacs SD, Wiley KE, Sauvageot J, Chen HS, Gurganus R, Mangold LA, Trock BJ, Gronberg H, Duggan D, Carpten JD, Partin AW, Walsh PC, Xu J, Isaacs WB. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. *J Natl Cancer Inst.* 2007; 99(20):1525–1533. [PubMed: 17925536]
 15. Delongchamps NB, Peyromaure M. The role of vascular endothelial growth factor in kidney and prostate cancer. *Can J Urol.* 2007; 14(5):3669–3677. [PubMed: 17949520]
 16. Benn-Torres J, Bonilla C, Robbins CM, Waterman L, Moses TY, Hernandez W, Santos ER, Bennett F, Aiken W, Tullock T, Coard K, Hennis A, Wu S, Nemesure B, Leske MC, Freeman V, Carpten J, Kittles RA. Admixture and population stratification in African Caribbean populations. *Ann Hum Genet.* 2008; (72)(1):90–98. [PubMed: 17908263]
 17. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. *Am J Hum Genet.* 2000; 67(1):170–181. [PubMed: 10827107]
 18. Zak NB, Shifman S, Shalom A, Darvasi A. Population-based gene discovery in the post-genomic era. *Drug Discov Today.* 2001; 6(21):1111–1115. [PubMed: 11677168]
 19. Hennis AJ, Hambleton IR, Wu SY, Skeete DH, Nemesure B, Leske MC. Prostate cancer incidence and mortality in barbados, west indies. *Prostate Cancer.* 2011; 2011:565230. [PubMed: 22110989]
 20. Glover FE Jr, Coffey DS, Douglas LL, Cadogan M, Russell H, Tulloch T, Baker TD, Wan RL, Walsh PC. The epidemiology of prostate cancer in Jamaica. *The Journal of urology.* 1998; 159(6): 1984–1986. discussion 1986–1987. [PubMed: 9598503]
 21. Nemesure B, Wu SY, Hennis A, Leske MC. Central adiposity and Prostate Cancer in a Black Population. *Cancer Epidemiol Biomarkers Prev.* 2012; 21(5):851–858. [PubMed: 22402288]
 22. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, Camargo A, Defelice M, Faggart M, Goyette M, Gupta S, Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl E, Winchester E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang W, Chu X, He Y, Jin L, Liu Y, Sun W, Wang H, Wang Y,

Xiong X, Xu L, Waye MM, Tsui SK, Xue H, Wong JT, Galver LM, Fan JB, Gunderson K, Murray SS, Oliphant AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, Leboeuf M, Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, Hudson TJ, Kwok PY, Cai D, Koboldt DC, Miller RD, Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, Mak W, Song YQ, Tam PK, Nakamura Y, Kawaguchi T, Kitamoto T, Morizono T, Nagashima A, Ohnishi Y, Sekine A, Tanaka T, Tsunoda T, Deloukas P, Bird CP, Delgado M, Dermizakis ET, Gwilliam R, Hunt S, Morrison J, Powell D, Stranger BE, Whittaker P, Bentley DR, Daly MJ, de Bakker PI, Barrett J, Chretien YR, Maller J, McCarroll S, Patterson N, Pe'er I, Price A, Purcell S, Richter DJ, Sabeti P, Saxena R, Schaffner SF, Sham PC, Varilly P, Stein LD, Krishnan L, Smith AV, Tello-Ruiz MK, Thorisson GA, Chakravarti A, Chen PE, Cutler DJ, Kashuk CS, Lin S, Abecasis GR, Guan W, Li Y, Munro HM, Qin ZS, Thomas DJ, McVean G, Auton A, Bottolo L, Cardin N, Eyheramendy S, Freeman C, Marchini J, Myers S, Spencer C, Stephens M, Donnelly P, Cardon LR, Clarke G, Evans DM, Morris AP, Weir BS, Mullikin JC, Sherry ST, Feolo M, Skol A, Zhang H, Matsuda I, Fukushima Y, Macer DR, Suda E, Rotimi CN, Adebamowo CA, Ajayi I, Aniagwu T, Marshall PA, Nkwodimmah C, Royal CD, Leppert MF, Dixon M, Peiffer A, Qiu R, Kent A, Kato K, Niikawa N, Adewole IF, Knoppers BM, Foster MW, Clayton EW, Watkin J, Muzny D, Nazareth L, Sodergren E, Weinstock GM, Yakub I, Birren BW, Wilson RK, Fulton LL, Rogers J, Burton J, Carter NP, Clee CM, Griffiths M, Jones MC, McLay K, Plumb RW, Ross MT, Sims SK, Willey DL, Chen Z, Han H, Kang L, Godbout M, Wallenburg JC, L'Archeveque P, Bellemare G, Saeki K, An D, Fu H, Li Q, Wang Z, Wang R, Holden AL, Brooks LD, McEwen JE, Guyer MS, Wang VO, Peterson JL, Shi M, Spiegel J, Sung LM, Zacharia LF, Collins FS, Kennedy K, Jamieson R, Stewart J. A second generation human haplotype map of over 3.1 million SNPs. *Nature*. 2007; 449(7164):851–861. [PubMed: 17943122]

23. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet*. 2009; 5(6):e1000529. [PubMed: 19543373]
24. Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. *Statistics in medicine*. 2002; 21(1):35–50. [PubMed: 11782049]
25. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. *American journal of epidemiology*. 2002; 155(5):478–484. [PubMed: 11867360]
26. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat Genet*. 2006; 38(2):209–213. [PubMed: 16415888]
27. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics*. 2003; 19(1):149–150. [PubMed: 12499305]
28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007; 81(3):559–575. [PubMed: 17701901]
29. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006; 38(8):904–909. [PubMed: 16862161]
30. Ng P, Schoenfeld ER, Hennis A, Wu SY, Leske MC, Nemesure B. Factors Influencing Prostate Cancer Healthcare Practices in Barbados, West Indies. *J Immigr Minor Health*. 2013 Jun; 15(3):653–660. [PubMed: 22669639]
31. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*. 2005; 21(2):263–265. [PubMed: 15297300]
32. Murphy AB, Ukoli F, Freeman V, Bennett F, Aiken W, Tulloch T, Coard K, Angwafo F, Kittles RA. 8q24 risk alleles in West African and Caribbean men. *Prostate*. 2012; 72(12):1366–1373. [PubMed: 22234922]
33. Okobia MN, Zmuda JM, Ferrell RE, Patrick AL, Bunker CH. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. *Prostate*. 2011; 71(10):1054–1063. [PubMed: 21557270]
34. Team, R. A language and environment for statistical computing. Vienna, Austria: 2007.

35. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010; 26(17):2190–2191. [PubMed: 20616382]
36. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Balter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. A common variant associated with prostate cancer in European and African populations. *Nat Genet*. 2006; 38(6):652–658. [PubMed: 16682969]
37. Benford ML, VanCleave TT, Lavender NA, Kittles RA, Kidd LR. 8q24 sequence variants in relation to prostate cancer risk among men of African descent: a case-control study. *BMC cancer*. 2010; 10:334. [PubMed: 20584312]
38. Cheng I, Plummer SJ, Jorgenson E, Liu X, Rybicki BA, Casey G, Witte JS. 8q24 and prostate cancer: association with advanced disease and meta-analysis. *Eur J Hum Genet*. 2008; 16(4):496–505. [PubMed: 18231127]
39. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeny LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. *Nat Genet*. 2007; 39(5):631–637. [PubMed: 17401366]
40. Robbins C, Torres JB, Hooker S, Bonilla C, Hernandez W, Candreva A, Ahaghotu C, Kittles R, Carpten J. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. *Genome Res*. 2007; 17(12):1717–1722. [PubMed: 17978284]
41. Schumacher FR, Feigelson HS, Cox DG, Haiman CA, Albanes D, Buring J, Calle EE, Chanock SJ, Colditz GA, Diver WR, Dunning AM, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Kaaks R, Key T, Kolonel LN, Kraft P, Le Marchand L, Ma J, Pike MC, Riboli E, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Virtamo J, Andriole G, Gelmann E, Willett WC, Hunter DJ. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. *Cancer Res*. 2007; 67(7):2951–2956. [PubMed: 17409400]
42. Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD. Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. *Oncologist*. 2012; 17(3):312–320. [PubMed: 22382457]
43. Wang Y, Ray AM, Johnson EK, Zuhlke KA, Cooney KA, Lange EM. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study. *The Prostate*. 2011; 71(3):225–231. [PubMed: 20717903]
44. Xu J, Kibel AS, Hu JJ, Turner AR, Pruett K, Zheng SL, Sun J, Isaacs SD, Wiley KE, Kim ST, Hsu FC, Wu W, Torti FM, Walsh PC, Chang BL, Isaacs WB. Prostate cancer risk associated loci in African Americans. *Cancer Epidemiol Biomarkers Prev*. 2009; 18(7):2145–2149. [PubMed: 19549807]
45. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nat Genet*. 2007; 39(5):645–649. [PubMed: 17401363]
46. Bensen JT, Xu Z, Smith GJ, Mohler JL, Fonhtam ET, Taylor JA. Genetic polymorphism and prostate cancer aggressiveness: A case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. *The Prostate*. 2012

47. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, Diver WR, Witte JS, Chanock SJ, Kolb S, Signorello LB, Yamamura Y, Neslund-Dudas C, Thun MJ, Murphy A, Casey G, Sheng X, Wan P, Pooler LC, Monroe KR, Waters KM, Le Marchand L, Kolonel LN, Stram DO, Henderson BE. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. *PLoS Genet.* 2011; 7(5):e1001387. [PubMed: 21637779]
48. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, Burt N, Calle EE, Chanock S, Clavel-Chapelon F, Colditz GA, Cox DG, Feigelson HS, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn JN, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Le Marchand L, Lenner P, Lund E, Panico S, Peeters PH, Pike MC, Riboli E, Tjonneland A, Travis R, Trichopoulos D, Wacholder S, Ziegler RG. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. *Cancer Res.* 2007; 67(5):1893–1897. [PubMed: 17325027]
49. Hughes L, Zhu F, Ross E, Gross L, Uzzo RG, Chen DY, Viterbo R, Rebbeck TR, Giri VN. Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.* 2012; 21(1):53–60.
50. Ishak MB, Giri VN. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.* 2011; 20(8): 1599–1610.
51. Wang ZP, Li HQ. [Sample size requirements for association studies on gene-gene interaction in case-control study]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2004; 25(7):623–626. [PubMed: 15308047]
52. Murphy DG, Walton TJ, Connolly S, Costello AJ. Focal therapy for localised prostate cancer: are we asking the correct research questions? *BJU Int.* 2012; 109(1):1–3. [PubMed: 22151749]

Figure 1.

Haploview image for chromosome 8q24 from the PRCA association study of 10 SNPs. Note that the residual r^2 pairwise linkage disequilibrium (LD) values from Haploview displayed above are multiplied times a factor of 100.

Table 1
Distribution of Minor Allele Frequencies (MAF) for 8q24 SNPs Genotyped in PCBP Cases and Controls

SNP	Region	Position *	MAF	Cases	Controls	Estimated Power (Average GRR=1.55 *)	Minimum GRR for 80% Power *
rs12547950	Near 4	123616097	G	0.31	0.32	99	1.31
rs7008482	4	126267630	T	0.10	0.18	91	1.46
rs2124036	Between 2 and 4	126648134	T	0.16	0.21	97	1.38
rs780321	Between 2 and 4	127083695	C	0.22	0.24	99	1.34
rs16901979	2	128124916	A	0.50	0.47	99	1.31
rs7818556	1	128484399	G	0.37	0.35	99	1.30
rs1447295	1	128485038	A	0.35	0.34	99	1.31
rs4427136	Near 1	128879839	G	0.22	0.24	99	1.34
rs2302793	Near 1	129108697	A	0.11	0.12	92	1.44
rs11780763	Near 1	129596286	T	0.09	0.10	88	1.48

* Log-additive model, 5% disease prevalence, $p < 0.05$

* GRCh37/hg 19 (February 2009)

Table II

Association of 8q24 Alleles and Genotypes with Prostate Cancer Risk in PCBP

SNP	Tested Allele or Genotype	Cases (N=532)	Controls (N=513)	OR (95% CI)	P-value	Permuted P-value (n=5000)
rs12547950	A	706	690	1.0 (0.9–1.2)	0.70	1
	A/A	238	228	1.1 (0.7–1.7)	0.79	1
	G/A	232	234	1.0 (0.6–1.6)	0.98	
	G/G	45	47	1.0		
rs7008482	G	921	898	1.2 (0.9–1.5)	0.29	0.94
	G/G	423	402	2.1 (0.8–5.5)	0.15	0.74
	G/T	93	96	1.9 (0.7–5.4)	0.20	
	T/T	6	12	1.0		
rs2124036	C	854	797	1.4 (1.1–1.7)	0.01	0.05
	C/C	356	320	2.7 (1.3–5.3)	0.01	0.03
	C/T	144	159	2.2 (1.1–4.4)	0.03	
	T/T	12	29	1.0		
rs780321	T	797	765	1.2 (0.9–1.4)	0.19	0.82
	T/T	311	293	1.5 (0.9–2.6)	0.14	0.72
	T/C	175	179	1.4 (0.8–2.4)	0.26	
	C/C	25	34	1.0		
rs16901979	A	520	474	1.2 (1.0–1.4)	0.07	0.43
	A/A	127	120	1.4 (1.0–1.9)	0.08	0.51
	A/C	270	236	1.4 (1.1–1.9)	0.02	
	C/C	123	154	1.0		
rs7818556	G	378	358	1.1 (0.9–1.3)	0.46	0.99
	G/G	71	68	1.1 (0.7–1.6)	0.62	1
	G/A	239	222	1.1 (0.8–1.5)	0.33	
	A/A	221	221	1.0		
rs1447295	A	360	347	1.0 (0.87–1.2)	0.67	1
	A/A	68	66	1.1 (0.7–1.6)	0.77	1

SNP	Tested Allele or Genotype	Cases (N=532)	Controls (N=513)	OR (95% CI)	P-value	Permuted P-value (n=5000)
	A/C	224	215	1.1 (0.8–1.4)	0.64	
	C/C	223	226	1.0		
rs4427136	A	804	772	1.1 (0.9–1.4)	0.25	0.89
	A/A	319	298	1.3 (0.8–2.3)	0.29	0.95
	A/G	172	176	1.2 (0.7–2.1)	0.50	
	G/G	27	34	1.0		
rs2302793	A	107	127	0.8 (0.6–1.1)	0.19	0.81
	A/A	8	6	1.3 (0.4–3.7)	0.67	1
	G/A	91	115	0.8 (0.6–1.0)	0.07	
	G/G	409	388	1.0		
rs11780763	G	926	915	1.0 (0.8–1.4)	0.88	1
	G/G	418	414	1.7 (0.4–7.1)	0.48	1
	G/T	90	87	1.7 (0.4–7.4)	0.47	
	T/T	3	7	1.0		

Table 3

Comparison of 8q24 PC Risk Alleles in 3 African Caribbean Populations

SNP	Region	Position *	Allele	Frequency in Cases	Frequency in Controls	OR	95% CI	P-value
Barbados								
rs7008482	4	126267630	G	0.9	0.88	1.9	0.7–5.4	0.2
rs16901979	2	128124916	A	0.51	0.47	1.4	1.1–1.9	0.02
rs6983267	3	128413305	N/A	N/A	N/A	N/A	N/A	N/A
rs1447295	1	128485038	A	0.35	0.34	1.1	0.82–1.4	0.6
Jamaica (Murphy 2012)								
rs7008482	4	126267630	G	0.88	0.88	0.9	0.5–1.8	0.98
rs16901979	2	128124916	A	0.5	0.5	1	0.6–1.4	0.93
rs6983267	3	128413305	G	0.91	0.89	1.1	0.6–2.5	0.68
rs1447295	1	128485038	A	0.39	0.31	1.4	0.9–2.1	0.14
Tobago (Okobia 2011)								
rs7008482	4	126267630	N/A	N/A	N/A	N/A	N/A	N/A
rs16901979	2	128124916	A	0.53	0.46	1.41	1.02–1.95	0.03
rs6983267	3	128413305	T	0.05	0.06	0.83	0.53–1.29	0.4
rs1447295	1	128485038	A	0.33	0.37	0.83	0.62–1.10	0.19

* GRCh37/hg19 (February 2009)

Table 4

A Meta-analyses Results in Common 8q24 Risk Alleles in African Caribbean Populations			
Random effects (DerSimonian-Laird)			
Population	OR	(95% CI)	Heterogeneity (P-value); Estimated Variance
rs16901979			
Barbados	1.18	(0.90–1.55)	
Jamaica (Murphy 2012)	1.00	(0.58–1.71)	
Tobago (Okobia 2011)	1.32	(0.99–1.76)	
Summary	1.21	(1.01–1.46)	0.87 (0.6462); 0
rs1447295			
Barbados	1.09	(0.82–1.45)	
Jamaica (Murphy 2012)	1.43	(0.81–2.52)	
Tobago (Okobia 2011)	0.84	(0.63–1.13)	
Summary	1.02	(0.79–1.32)	3.18 (0.2043); 0.02

B Meta-analyses Results in Common 8q24 Risk Alleles in African Caribbean Populations			
Fixed effects (Mantel-Haenszel)			
Population	OR	(95% CI)	Heterogeneity (P-value)
rs16901979			
Barbados	1.18	(0.90–1.55)	
Jamaica (Murphy 2012)	1.00	(0.58–1.71)	
Tobago (Okobia 2011)	1.32	(0.99–1.76)	
Summary	1.21	(1.01–1.46)	0.87 (0.65)
rs1447295			
Barbados	1.09	(0.82–1.45)	
Jamaica (Murphy 2012)	1.43	(0.81–2.52)	
Tobago (Okobia 2011)	0.84	(0.63–1.13)	
Summary	1	(0.83–1.22)	3.18 (0.20)